SAFETY EVALUATION OF RITUXIMAB OFF-LABEL USE FOR SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES

P Pascual, P Carmona, J Barral, M Umeren, B Iraustorza, A Aranguren, G Lizaga, A Asensio, E Esañola, K Andueza. Donostia University Hospital, Pharmacy Service, San Sebastián, Spain

Background Systemic Autoimmune Rheumatic Diseases (SARDs) are a group of syndromes caused by antibodies inflammation related. Rituximab is a biological drug that targets antigen CD-20 present on the surface of B-Lymphocytes and thus potentially active against SARDs refractory to conventional treatment: steroids and immunosuppressors.

Purpose To describe and evaluate safety parameters of the risk management protocol for adults SARDs patients treated with off-label Rituximab.

Materials and Methods Descriptive-observational study from January 2011 to July 2012 realised by the Pharmacy and Rheumatology Service. Data were obtained from electronic medical records. Three types of risk management protocol data were evaluated. A) Clinical parameters: infection (including Tuberculosis), cardiovascular disease, severe cytopenia, neoplasia or new neurological symptoms. B) Complementary tests: hemogram and general biochemistry while on Rituximab. C) Others: adverse events related with Rituximab infusion.

Results 21 patients were included (mean age 52.71 ± 16.11 years). Diagnoses were Sjögren’s Syndrome (10), Systemic Lupus Erythematosus (4), Mixed Connective Tissue Disease (3), inflammatory myopathy (2), Systemic Sclerosis (1) and Wegener’s Granulomatosis (1).

- Clinical parameters: infection was detected on 5 patients (23%), severe cytopenia in 1 patient (4.7%) and peripheral neurological symptomatology in another one. No cardiovascular disease or neoplasia were detected.
- Complementary tests: patient presented severe thrombocytopenia (platelets < 20000/mCL).
- Adverse events infusion related: detected on 19% of patients.

Conclusions Rituximab off-label use for SARDs has increased over the last years and pharmacovigilance strategies as well as risk management protocols have proved useful identifying risks, controlling adverse events, improving quality of care and integrating Pharmacists into direct patient care.

No conflict of interest.

SAFETY OF SUNITINIB VERSUS PAZOPANIB IN METASTATIC RENAL CANCER IN A TERTIARY HOSPITAL

M Perez, T Desongles, H Acosta, J Cotrina, M Villalba, M Galván, E Alfaro. Hospital Universitario Virgen del Rocío, Servicio de Farmacia, Seville, Spain

Background Sunitinib and pazopanib are tyrosine kinase inhibitors used in the treatment of metastatic renal cancer. Pazopanib has been approved more recently, so the user experience is not as extensive as with sunitinib.

Purpose To evaluate the safety profile of pazopanib and sunitinib in patients with metastatic renal cancer.

To compare the incidence of adverse reactions between the two drugs.

Materials and Methods We identified patients treated with sunitinib and pazopanib at the hospital in the past two years, using the pharmacy database.

We looked at the medical records of patients through digital medical records, collecting dose patterns, line of therapy, adverse reactions detected, their severity and if dose reductions were necessary, using Excel.

Results A total of 26 patients with metastatic renal cancer were identified: 16 treated with sunitinib and 10 with pazopanib.

Assthenia was the most frequent drug-related toxic effect in both treatment groups, with an incidence of 93.75% for sunitinib and 60% for pazopanib.

Nausea/vomiting and diarrhoea were detected in 50% of patients treated with pazopanib. In sunitinib patients nausea/vomiting were detected in 6.25% of patients and diarrhoea was detected in 68.75% of patients.

For patients who received pazopanib, the rate of mucositis was 20%, whereas for those treated with sunitinib it was 75%. Palmar-plantar erythrodysesthesia syndrome occurred in 43.75% of those on sunitinib treatment, while none was detected for pazopanib, and the frequency of other skin pigmentation disorders for the two drugs was 62.5% and 30% respectively.

Blood pressure was decompensated in 37.5% of patients treated with sunitinib and 10% of those taking pazopanib, although most patients required antihypertensive drugs to get better control.

Dose adjustment was required of sunitinib in 43.75% of cases and in 25% pazopanib.

No conflict of interest.
Conclusions Pazopanib may be better tolerated than sunitinib, with an acceptable adverse event profile and fewer dose adjustments.

Also, the severity of adverse events looks lower with pazopanib. However, the number of patients was too small to arrive at definitive conclusions, so it is necessary to enlarge this study.

No conflict of interest.

**Table 1**

| SCREENING FOR CLINICALLY RELEVANT INTERACTIONS IN LIVER TRANSPLANT PATIENTS |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| C. Andrés González, RM Romero Jiménez, V. Valverde Alcalá, M. Muñoz Castillo, HRU CARLOS HAYA, Pharmacy, Malaga, Spain; HRU GREGORIO MARAÑÓN, Pharmacy, Madrid, Spain; HRU CARLOS HAYA, pharmacy, Madrid, Spain |

**Background** Drug-drug interactions are a frequent problem in liver transplant (LT) patients, further hindering pharmacotherapeutic management, which is a very important risk to the patient’s life.

**Purpose** To detect drug-drug interaction of clinical relevance in LT patients in a tertiary hospital.

**Materials and Methods** Descriptive transversal study of the LT patients in our hospital during 2011 who were admitted to the Digestive Surgery Unit (DSU). Variables analysed were: sex, number of drugs prescribed at admission and number of days of hospitalisation in the DSU. Data were collected from clinical and pharmacotherapeutic histories and the unit dose dispensing log. Drug-drug interactions were detected and analysed by the Micromedex Healthcare series® database. The results were analysed with the SPSS v.19 statistics software.

**Results** Of a total of 51 transplant patients, we included 44 (5 patients died and in 2 patients the medicines were not recorded at admission to the DSU).

75% of patients were male and 25% female, mean age of patients was 53 ± 12 years. The median number of days in hospital was 11 [9.18] days. The mean number of drugs prescribed on admission was 11 ± 2.5 drugs/patient.

The total number of drug interactions detected was 210 of which 158 (72.9%) were clinically relevant, representing a prevalence of 94.1% of liver transplant patients.

Of the main variables studied, only the number of drugs prescribed was found to be directly proportional (p < 0.05) to the number of clinically relevant interactions detected, thus no relationship was obtained between age or the number of days hospitalised.

**Conclusions** Liver transplant patients are critically ill patients with highly complex treatment. A high prevalence of clinically relevant interactions was detected related to polypharmacy and the use of high-risk medicines.

The presence of a pharmacist in this Unit would be beneficial to comprehensively review these patients’ treatment.

No conflict of interest.

**Table 2**

| SECURING INTRatheCAL INJECTIONS: WHAT ABOUT NON-Luer CONNECTORS? |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| S. Schietecatte, M. Egot, G. Marliot, I. Sakji, J. L. Cazin. Centre Oscar Lambret, Nord, Lille Cedex, France |

**Background** Episodes of accidental injection of medicines intended for intravenous administration into the intrathecal space have been reported worldwide, often leading to death. Since 2001, international guidelines have been issued to prevent such risks. A major recommendation is to develop a non-luer connector to use in neuraxial procedures.

**Purpose** To give an overview of the development and marketing of medical devices fitted with non-luer connectors.

**Materials and Methods** Manufacturers’ catalogues have been consulted. A literature review was conducted using the PubMed and Science Direct databases, including the following MeSH keywords ‘non-luer’, ‘connectors’, ‘safety’ and ‘intrathecal’. European Health Authorities websites have been also consulted. All searches were performed between August and October 2012.

**Results** The United Kingdom, which has been a pioneer in guidance, was the first to implement such connectors. Five different non-luer connectors have been designed thanks to the National Patient Safety Agency (NPSA) initiative. Literature research identified few individual tests of these new devices. Some incidents such as mismatching connectors have been documented. So the NPSA has updated recommendations about introducing secure non-luer connectors. These devices are coming onto the French and Belgian market soon. To our knowledge safety connectors are not yet available in other countries.

**Conclusions** Non-luer connectors for intrathecal drug administration were initially launched in Great Britain. This process obviously